Quote | Lyell Immunopharma Inc. (NASDAQ:LYEL)
Last: | $2.78 |
---|---|
Change Percent: | 0.0% |
Open: | $2.61 |
Close: | $2.78 |
High: | $2.8 |
Low: | $2.55 |
Volume: | 647,926 |
Last Trade Date Time: | 05/16/2024 03:00:00 am |
News | Lyell Immunopharma Inc. (NASDAQ:LYEL)
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team wil...
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarter On track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced TIL product candidate, in the secon...
Message Board Posts | Lyell Immunopharma Inc. (NASDAQ:LYEL)
Subject | By | Source | When |
---|---|---|---|
Preclinical data from another group (LYL119 will be | jondoeuk | investorshub | 04/28/2023 9:29:39 PM |
LYEL..........................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0 | glenn1919 | investorshub | 03/01/2023 4:03:25 PM |
The FDA has cleared an IND for LYL845. | jondoeuk | investorshub | 10/10/2022 12:23:15 AM |
SITC titles | jondoeuk | investorshub | 10/05/2022 7:32:53 PM |
recent technical advances using culture conditions with IL-7/IL-15 and | NY1972 | investorshub | 07/27/2022 2:39:15 AM |
News, Short Squeeze, Breakout and More Instantly...
Lyell Immunopharma Inc. Company Name:
LYEL Stock Symbol:
NASDAQ Market:
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical?stage T-cell reprogramming co...
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team wil...
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarter On track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced TIL product candidate, in the secon...